Nuvectis Total Assets from 2010 to 2024
NVCT Stock | USD 4.90 0.17 3.35% |
Total Assets | First Reported 2010-12-31 | Previous Quarter 19.2 M | Current Value 14.5 M | Quarterly Volatility 4.9 M |
Check Nuvectis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nuvectis Pharma's main balance sheet or income statement drivers, such as Interest Expense of 179.9 K, Selling General Administrative of 4.6 M or Selling And Marketing Expenses of 13.2 K, as well as many indicators such as Price To Sales Ratio of 510, Dividend Yield of 0.0 or PTB Ratio of 11.17. Nuvectis financial statements analysis is a perfect complement when working with Nuvectis Pharma Valuation or Volatility modules.
Nuvectis | Total Assets |
Latest Nuvectis Pharma's Total Assets Growth Pattern
Below is the plot of the Total Assets of Nuvectis Pharma over the last few years. Total assets refers to the total amount of Nuvectis Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Nuvectis Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Nuvectis Pharma's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nuvectis Pharma's overall financial position and show how it may be relating to other accounts over time.
View | Last Reported 19.18 M | 10 Years Trend |
|
Total Assets |
Timeline |
Nuvectis Total Assets Regression Statistics
Arithmetic Mean | 8,934,840 | |
Geometric Mean | 8,109,439 | |
Coefficient Of Variation | 54.37 | |
Mean Deviation | 3,644,544 | |
Median | 6,657,000 | |
Standard Deviation | 4,858,037 | |
Sample Variance | 23.6T | |
Range | 13.7M | |
R-Value | 0.65 | |
Mean Square Error | 14.5T | |
R-Squared | 0.43 | |
Significance | 0.01 | |
Slope | 711,247 | |
Total Sum of Squares | 330.4T |
Nuvectis Total Assets History
Other Fundumenentals of Nuvectis Pharma
Nuvectis Pharma Total Assets component correlations
Click cells to compare fundamentals
About Nuvectis Pharma Financial Statements
Nuvectis Pharma shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Nuvectis Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Nuvectis Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Nuvectis Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last Reported | Projected for Next Year | ||
Total Assets | 19.2 M | 14.5 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.